Adagene (FRA:978) ROE % Adjusted to Book Value: -9.69% (As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.58
GF Value €12.09
! 5 Warning Signs
View Full Analysis

What is Adagene ROE % Adjusted to Book Value?

Adagene FRA:978 -1.10% 42 ROE % Adjusted to Book Value is -9.69% as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €12.09. The stock has 5 warning signs investors should review.

Adagene's ROE % for the quarter that ended in Dec. 2025 was -22.39%. Adagene's PB Ratio for the quarter that ended in Dec. 2025 was 2.31. Adagene's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -9.69%.

Adagene ROE % Adjusted to Book Value Related Terms

Adagene ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Adagene's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene ROE % Adjusted to Book Value Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -58.54 -115.97 -23.79 -31.93 -16.60

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.81 -23.13 -35.13 -25.05 -9.69

FRA:978 vs RNAC, LYEL, ALXO: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Adagene's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Adagene's ROE % Adjusted to Book Value falls into.


FRA:978
42GF Score
Adagene Inc FRA:978
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene ROE % Adjusted to Book Value Calculation

Adagene's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-38.34% / 2.31
=-16.60%

Adagene's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-22.39% / 2.31
=-9.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.69% mean?
Adagene (FRA:978) has a ROE % Adjusted to Book Value of -9.69% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adagene and its competitors.
Is Adagene's ROE % Adjusted to Book Value too high?
Adagene's current ROE % Adjusted to Book Value is -9.69%. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's ROE % Adjusted to Book Value compare to RNAC and LYEL?
Adagene's ROE % Adjusted to Book Value of -9.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adagene and its competitors. Adagene's current ROE % Adjusted to Book Value is -9.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current ROE % Adjusted to Book Value of -9.69%. The stock's GF Value™ is €12.09, compared to a current price of €3.58 — trading 70.4% below its estimated fair value. The current ROE % Adjusted to Book Value is -9.69%. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Adagene (FRA:978), the current ROE % Adjusted to Book Value is -9.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.58 is trading 70.4% below its estimated GF Value™ of €12.09.

Key valuation signals for FRA:978:

  • ROE % Adjusted to Book Value: -9.69%
  • GF Value™: €12.09 vs. price of €3.58 (70.4% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.58
Price
€12.09
GF Value